Opioid Use Disorder in Pregnancy in Long-Term Maternal/Infant Outcomes

Launched by SENTHIL SADHASIVAM · Apr 18, 2019

Keywords

ClinConnect Summary

This clinical trial is looking to understand how both medical history and genetics affect pregnant women who are using buprenorphine to treat opioid use disorder. The goal is to identify which mothers might struggle with their treatment and which babies could be at higher risk for experiencing withdrawal symptoms after birth, a condition known as neonatal abstinence syndrome (NAS).

To participate in this study, women must be at least 18 years old, currently taking buprenorphine, and enrolled in a prenatal program at IU Health University Hospital. They also need to be pregnant with one baby and plan to deliver at Methodist, University, or Riley Hospital. Participants can expect to provide information about their health and possibly undergo some tests to help researchers gather important data. This study is actively recruiting participants, and understanding more about these factors could lead to better care for both mothers and their babies in the future.

Gender

FEMALE

Eligibility criteria

• Inclusion Criteria:
• • Age greater 18 years
• • Currently taking Buprenorphine for Opioid Use Disorder and enrolled in a prenatal opioid maintenance program in the antenatal clinic at IU Health University Hospital.
• • Pregnant with single baby
• • Planned delivery at Methodist, University or Riley Hospital
• Exclusion Criteria:
• • Serious maternal medical illness as deemed by study physician or investigator.
• • Known or suspected major fetal/neonatal congenital abnormalities.